Immunitybio Inc (IBRX)vsRevolution Medicines Inc (RVMD)
IBRX
Immunitybio Inc
$6.92
-5.08%
HEALTHCARE · Cap: $7.88B
RVMD
Revolution Medicines Inc
$155.69
+3.11%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Immunitybio Inc generates 18900% more annual revenue ($140.98M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. IBRX earns a higher WallStSmart Score of 28/100 (F).
IBRX
Avoid28
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 167.6% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
Negative free cash flow — burning cash
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IBRX
The strongest argument for IBRX centers on Revenue Growth, Debt/Equity. Revenue growth of 167.6% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : IBRX
The primary concerns for IBRX are EPS Growth, Return on Equity, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
IBRX profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
IBRX is growing revenue faster at 167.6% — sustainability is the question.
IBRX generates stronger free cash flow (-77M), providing more financial flexibility.
Bottom Line
IBRX scores higher overall (28/100 vs 24/100) and 167.6% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immunitybio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?